HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ainhoa Arina Selected Research

superagonist SIYR

1/2017Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.
7/2016Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ainhoa Arina Research Topics

Disease

35Neoplasms (Cancer)
11/2021 - 01/2002
5Carcinoma (Carcinomatosis)
02/2006 - 09/2003
3Bites and Stings (Sting)
01/2019 - 11/2014
2Melanoma (Melanoma, Malignant)
01/2021 - 08/2013
2Colorectal Neoplasms (Colorectal Cancer)
11/2007 - 08/2005
1Glioblastoma (Glioblastoma Multiforme)
11/2021
1Glioma (Gliomas)
11/2021
1Chromosomal Instability (Chromosome Stability)
01/2019
1Carcinogenesis
04/2015
1Pancreatic Neoplasms (Pancreatic Cancer)
08/2005
1Hepatocellular Carcinoma (Hepatoma)
08/2005
1Hepatitis C
05/2005
1Infections
05/2004
1Colonic Neoplasms (Colon Cancer)
05/2004
1Persistent Infection
10/2003

Drug/Important Bio-Agent (IBA)

12AntigensIBA
01/2017 - 12/2002
8Monoclonal AntibodiesIBA
11/2008 - 01/2002
6Neoplasm Antigens (Tumor Antigens)IBA
11/2021 - 01/2002
4Interleukin-12 (IL 12)IBA
08/2005 - 09/2003
3InterferonsIBA
01/2021 - 01/2018
3Peptides (Polypeptides)IBA
01/2021 - 05/2012
3Proteins (Proteins, Gene)FDA Link
01/2016 - 02/2006
3T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2016 - 12/2002
3CytokinesIBA
11/2013 - 01/2002
2CDC2 Protein Kinase (Protein p34cdc2)IBA
11/2021 - 01/2019
2Interferon-gamma (Interferon, gamma)IBA
01/2019 - 06/2011
2DNA (Deoxyribonucleic Acid)IBA
01/2018 - 11/2014
2superagonist SIYRIBA
01/2017 - 07/2016
2Isoantigens (Alloantigen)IBA
01/2017 - 05/2004
2ChemokinesIBA
07/2016 - 08/2005
2RNA (Ribonucleic Acid)IBA
01/2016 - 02/2006
2Histocompatibility Antigens Class IIBA
05/2012 - 06/2011
1Alkylating AgentsIBA
11/2021
1Temozolomide (Temodar)FDA LinkGeneric
11/2021
1B7-H1 AntigenIBA
01/2021
1pembrolizumabIBA
01/2018
1Therapeutic UsesIBA
01/2018
1Immune Checkpoint InhibitorsIBA
01/2017
1VaccinesIBA
07/2016
1CollagenIBA
01/2016
1Tumor Viral Antigens (Large T Antigen)IBA
01/2016
1NucleotidesIBA
01/2016
1Collagen Type I (Type I Collagen)IBA
01/2016
1cyclic guanosine monophosphate-adenosine monophosphateIBA
11/2014
1Interferon Type IIBA
11/2014
1Blocking AntibodiesIBA
08/2013
1Bacterial VaccinesIBA
08/2013
1DEAD-box RNA HelicasesIBA
05/2012
1PerforinIBA
04/2012
1Interleukin-15 (Interleukin 15)IBA
04/2012
1Interleukin-15 Receptors (Interleukin 15 Receptor)IBA
04/2012
1I-antigenIBA
06/2011
1Complementary DNA (cDNA)IBA
09/2009
1Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA
11/2007
1Thymidine KinaseIBA
07/2006
1Interleukin-8 (Interleukin 8)IBA
08/2005
1Interleukin-8 ReceptorsIBA
08/2005
1Chemokine CCL19IBA
08/2005
1Antineoplastic Agents (Antineoplastics)IBA
11/2003
1OvalbuminIBA
09/2003

Therapy/Procedure

12Immunotherapy
01/2021 - 01/2002
11Therapeutics
11/2021 - 11/2003
6Radiotherapy
11/2021 - 11/2014
2Injections
08/2005 - 05/2004
1Radioimmunotherapy
01/2021
1Cell- and Tissue-Based Therapy (Cell Therapy)
05/2012
1Drug Therapy (Chemotherapy)
11/2007